LY3853113

Eli Lilly and Company · Phase 2 active Small molecule

At a glance

Generic name	LY3853113
Also known as	bebtelovimab
Sponsor	Eli Lilly and Company
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness (PHASE2, PHASE3)
A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

LY3853113 CI brief — competitive landscape report
LY3853113 updates RSS · CI watch RSS
Eli Lilly and Company portfolio CI